5Cohn JN.Rationale for angiotensin Ⅱ receptor blocker therapy in chronic heart failure[J].Renin Angiotensin Aldosterone Syst,2000,(1 Suppl 2):38-40.
6Jorde UP.Suppression of the renin-angiotensin-aldosterone system in chronic heart failure:choice of agents and clinical impact[J].Cardiol Rev,2006,14(2):81-87.
7Konstam MA,Rousseau MF,Kronenberg MW,et al.Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure.SOLVD Investigators[J].Circulation,1992,86(2):431-438.
8Voros S,Yang Z,Bove CM,et al.Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling[J].Am J Physiol Heart Circ Physiol,2006,290 (3):H1004-H1010.
9Cohn JN.Structural basis for heart failure.Ventricular remodeling and its pharmacological inhibition[J].Circulation,1995,15;91(10):2504-2507.
10Miller WL,Hartman KA,Burritt MF,et al.Troponin,B-type natriuretic peptides and outcomes in severe heart failure:differences between ischemic and dilated cardiomyopathies[J].Clin Cardiol,2007,30(5):245-250.
二级参考文献1
1Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
9Horwich TB,Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure[J]. Circulation,2003,108(7) :833-838.
10Waxman DA. Troponin I is an independent predictor of allcause mortality in hospitalized patients with congestive heart failure[J]. Am Heart J ,2007,154(5) :e27.
